144 related articles for article (PubMed ID: 24407024)
21. Mutation of cysteine 111 in Dopa decarboxylase leads to active site perturbation.
Dominici P; Moore PS; Castellani S; Bertoldi M; Voltattorni CB
Protein Sci; 1997 Sep; 6(9):2007-15. PubMed ID: 9300500
[TBL] [Abstract][Full Text] [Related]
22. Mutation of tyrosine 332 to phenylalanine converts dopa decarboxylase into a decarboxylation-dependent oxidative deaminase.
Bertoldi M; Gonsalvi M; Contestabile R; Voltattorni CB
J Biol Chem; 2002 Sep; 277(39):36357-62. PubMed ID: 12118007
[TBL] [Abstract][Full Text] [Related]
23. Expression of enzymatically active L-DOPA decarboxylase in human peripheral leukocytes.
Kokkinou I; Nikolouzou E; Hatzimanolis A; Fragoulis EG; Vassilacopoulou D
Blood Cells Mol Dis; 2009; 42(1):92-8. PubMed ID: 19041269
[TBL] [Abstract][Full Text] [Related]
24. Release of membrane-associated L-dopa decarboxylase from human cells.
Chalatsa I; Fragoulis EG; Vassilacopoulou D
Neurochem Res; 2011 Aug; 36(8):1426-34. PubMed ID: 21479916
[TBL] [Abstract][Full Text] [Related]
25. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
[TBL] [Abstract][Full Text] [Related]
26. Parkinson's Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors.
Montioli R; Voltattorni CB; Bertoldi M
Curr Drug Metab; 2016; 17(5):513-8. PubMed ID: 27025882
[TBL] [Abstract][Full Text] [Related]
27. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine).
Christenson JG; Dairman W; Udenfriend S
Proc Natl Acad Sci U S A; 1972 Feb; 69(2):343-7. PubMed ID: 4536745
[TBL] [Abstract][Full Text] [Related]
28. Decarboxylation-dependent transamination catalyzed by mammalian 3,4-dihydroxyphenylalanine decarboxylase.
O'Leary MH; Baughn RL
J Biol Chem; 1977 Oct; 252(20):7168-73. PubMed ID: 561784
[TBL] [Abstract][Full Text] [Related]
29. Pyridoxal 5'-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states.
Allen GF; Neergheen V; Oppenheim M; Fitzgerald JC; Footitt E; Hyland K; Clayton PT; Land JM; Heales SJ
J Neurochem; 2010 Jul; 114(1):87-96. PubMed ID: 20403077
[TBL] [Abstract][Full Text] [Related]
30. Transaldimination induces coenzyme reorientation in pig kidney dopa decarboxylase.
Moore PS; Dominici P; Voltattorni CB
Biochimie; 1995; 77(9):724-28. PubMed ID: 8789463
[TBL] [Abstract][Full Text] [Related]
31. A Study for Therapeutic Treatment against Parkinson's Disease via Chou's 5-steps Rule.
Lan J; Liu Z; Liao C; Merkler DJ; Han Q; Li J
Curr Top Med Chem; 2019; 19(25):2318-2333. PubMed ID: 31629395
[TBL] [Abstract][Full Text] [Related]
32. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
33. Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
Daidone F; Montioli R; Paiardini A; Cellini B; Macchiarulo A; Giardina G; Bossa F; Borri Voltattorni C
PLoS One; 2012; 7(2):e31610. PubMed ID: 22384042
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview.
Cellini B; Montioli R; Oppici E; Voltattorni CB
Open Biochem J; 2012; 6():131-8. PubMed ID: 23264832
[TBL] [Abstract][Full Text] [Related]
35. An anomalous side reaction of the Lys303 mutant aromatic L-amino acid decarboxylase unravels the role of the residue in catalysis.
Nishino J; Hayashi H; Ishii S; Kagamiyama H
J Biochem; 1997 Mar; 121(3):604-11. PubMed ID: 9133632
[TBL] [Abstract][Full Text] [Related]
36. Open conformation of human DOPA decarboxylase reveals the mechanism of PLP addition to Group II decarboxylases.
Giardina G; Montioli R; Gianni S; Cellini B; Paiardini A; Voltattorni CB; Cutruzzolà F
Proc Natl Acad Sci U S A; 2011 Dec; 108(51):20514-9. PubMed ID: 22143761
[TBL] [Abstract][Full Text] [Related]
37. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
38. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
Foster SB; Wrona MZ; Han J; Dryhurst G
Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive picture of the mutations associated with aromatic amino acid decarboxylase deficiency: from molecular mechanisms to therapy implications.
Montioli R; Dindo M; Giorgetti A; Piccoli S; Cellini B; Voltattorni CB
Hum Mol Genet; 2014 Oct; 23(20):5429-40. PubMed ID: 24865461
[TBL] [Abstract][Full Text] [Related]
40. Dye-sensitized photo-oxidation of pig kidney Dopa decarboxylase.
Pasqua A; Dominici P; Murgia SM; Poletti A; Borri Voltattorni C
Biochem Int; 1984 Oct; 9(4):437-46. PubMed ID: 6517952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
